Match!
William Zigrang
Placebo-controlled studyHazard ratioPlaceboType 2 diabetesDulaglutide
2Publications
2H-index
70Citations
What is this?
Publications 2
Newest
#1Hertzel C. Gerstein (Population Health Research Institute)H-Index: 93
#2Helen M. Colhoun (Edin.: University of Edinburgh)H-Index: 50
Last. William ZigrangH-Index: 2
view all 1456 authors...
Summary Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analysis of the REWIND trial of the effect of dulaglutide on cardiovascular disease. Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial at 371 sites in 24 countries. Men and women aged at leas...
18 CitationsSource
#1Hertzel C. Gerstein (Population Health Research Institute)H-Index: 93
#2Helen M. Colhoun (Edin.: University of Edinburgh)H-Index: 50
Last. William ZigrangH-Index: 2
view all 1456 authors...
Summary Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A 1c (HbA 1c ) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of...
52 CitationsSource
1